https://scholars.lib.ntu.edu.tw/handle/123456789/484020
標題: | Considerations of heterogeneity in clinical trials for hepatocellular carcinoma | 作者: | TSUNG-HAO LIU YU-YUN SHAO LI-CHUN LU Ying-Chun Shen CHIUN HSU ZHONG-ZHE LIN CHIH-HUNG HSU ANN-LII CHENG |
關鍵字: | Clinical trial | hepatocellular carcinoma | heterogeneity | trial design;Clinical trial; hepatocellular carcinoma; heterogeneity; trial design | 公開日期: | 3-七月-2019 | 卷: | 13 | 期: | 7 | 來源出版物: | Expert Review of Gastroenterology and Hepatology | 摘要: | © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Clinical trials in hepatocellular carcinoma (HCC) exhibit a high degree of heterogeneity. These heterogeneities may lead to unexpected results among clinical trials. Area covered: In this review, we address the heterogeneity noted in early phase HCC trials, trials involving transarterial chemoembolization, and advanced HCC trials. Furthermore, we discuss possible methods to attenuate the detrimental effects of heterogeneity when conducting clinical trials. Expert opinion: Clinical trials in HCC exhibit an inherently high degree of heterogeneity because of various reasons: tumor heterogeneity, different cirrhotic backgrounds, various etiologies of cirrhosis, and geographical differences in practice and expertise. Such heterogeneity may cause imbalance among the enrolled patient population, premature withdrawal from the clinical trial, and variable response to the treatment. In addition, methodological heterogeneity also exists in designing trial protocol and response evaluation. All these factors may eventually lead to conflicting results among clinical trials. Accounting for these heterogeneities is important to foster the success of future trials. In recent years, significant progress with molecular targeted agents and immune checkpoint inhibitors was made in advanced HCC. These new agents are also being tested in clinical trials involving earlier stage HCC and will also face the challenge of these issues. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/484020 | ISSN: | 17474124 | DOI: | 10.1080/17474124.2019.1621165 | SDG/關鍵字: | alpha fetoprotein; atezolizumab; bevacizumab; brivanib; cabozantinib; interferon; iodinated poppyseed oil; ipilimumab; lenvatinib; nivolumab; orantinib; pembrolizumab; placebo; ramucirumab; regorafenib; sorafenib; antineoplastic agent; adjuvant therapy; cancer prognosis; cancer staging; cell heterogeneity; chemoembolization; Child Pugh score; clinical practice; clinical trial (topic); geography; human; liver cell carcinoma; liver cirrhosis; liver resection; medical decision making; methodology; outcome assessment; overall survival; patient selection; progression free survival; recurrence free survival; recurrence risk; research subject; Review; treatment response; treatment withdrawal; unspecified side effect; chemoembolization; clinical trial (topic); immunotherapy; liver cell carcinoma; liver tumor; methodology; molecularly targeted therapy; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clinical Trials as Topic; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Research Design |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。